Mesothelin is overexpressed in pancreaticobiliary adenocarcinomas but not in normal pancreas and chronic pancreatitis - PubMed (original) (raw)
Comparative Study
. 2005 Dec;124(6):838-45.
Affiliations
- PMID: 16416732
Comparative Study
Mesothelin is overexpressed in pancreaticobiliary adenocarcinomas but not in normal pancreas and chronic pancreatitis
Raffit Hassan et al. Am J Clin Pathol. 2005 Dec.
Abstract
Mesothelin, a cell surface glycoprotein present on normal mesothelial cells, has been reported to be expressed in pancreatic adenocarcinomas. We conducted this study to fully characterize mesothelin expression in surgically resected, formalin-fixed, paraffin-embedded tissue specimens of 18 pancreatic adenocarcinomas, 9 adenocarcinomas of the ampulla of Vater, 12 adenocarcinomas of the common bile duct, and 17 cases of chronic pancreatitis. Mesothelin immunostaining was performed using the antimesothelin monoclonal antibody 5B2. All 18 cases (100%) of pancreatic adenocarcinomas showed mesothelin expression, as did 8 (89%) of 9 cases of ampullar adenocarcinoma and all 12 cases (100%) of common bile duct adenocarcinoma. In all cases of pancreaticobiliary adenocarcinoma, the adjacent normal pancreas did not stain for mesothelin. Of 17 specimens of chronic pancreatitis, 16 were negative for mesothelin expression, and 1 case showed weak mesothelin staining of fewer than 5% of normal pancreatic ducts. Our results demonstrated mesothelin expression in the majority of pancreaticobiliary adenocarcinomas and no expression in normal pancreatic tissues and in chronic pancreatitis.
Similar articles
- Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE).
Argani P, Iacobuzio-Donahue C, Ryu B, Rosty C, Goggins M, Wilentz RE, Murugesan SR, Leach SD, Jaffee E, Yeo CJ, Cameron JL, Kern SE, Hruban RH. Argani P, et al. Clin Cancer Res. 2001 Dec;7(12):3862-8. Clin Cancer Res. 2001. PMID: 11751476 - Value of mesothelin immunostaining in the diagnosis of mesothelioma.
Ordóñez NG. Ordóñez NG. Mod Pathol. 2003 Mar;16(3):192-7. doi: 10.1097/01.MP.0000056981.16578.C3. Mod Pathol. 2003. PMID: 12640097 - Immunocytochemical study of the expression of mesothelin in fine-needle aspiration biopsy specimens of pancreatic adenocarcinoma.
Baruch AC, Wang H, Staerkel GA, Evans DB, Hwang RF, Krishnamurthy S. Baruch AC, et al. Diagn Cytopathol. 2007 Mar;35(3):143-7. doi: 10.1002/dc.20594. Diagn Cytopathol. 2007. PMID: 17304533 - Mesothelin: a new target for immunotherapy.
Hassan R, Bera T, Pastan I. Hassan R, et al. Clin Cancer Res. 2004 Jun 15;10(12 Pt 1):3937-42. doi: 10.1158/1078-0432.CCR-03-0801. Clin Cancer Res. 2004. PMID: 15217923 Review. - Chronic pancreatitis and the differential diagnosis versus pancreatic cancer.
Klöppel G, Adsay NV. Klöppel G, et al. Arch Pathol Lab Med. 2009 Mar;133(3):382-7. doi: 10.5858/133.3.382. Arch Pathol Lab Med. 2009. PMID: 19260744 Review.
Cited by
- Rehabilitation for Functioning and Quality of Life in Patients with Malignant Pleural Mesothelioma: A Scoping Review.
Lippi L, de Sire A, Aprile V, Calafiore D, Folli A, Refati F, Balduit A, Mangogna A, Ivanova M, Venetis K, Fusco N, Invernizzi M. Lippi L, et al. Curr Oncol. 2024 Jul 30;31(8):4318-4337. doi: 10.3390/curroncol31080322. Curr Oncol. 2024. PMID: 39195305 Free PMC article. Review. - Biology of Mesothelin and Clinical Implications: A Review of Existing Literature.
Hagerty BL, Takabe K. Hagerty BL, et al. World J Oncol. 2023 Oct;14(5):340-349. doi: 10.14740/wjon1655. Epub 2023 Sep 20. World J Oncol. 2023. PMID: 37869242 Free PMC article. Review. - Listeria monocytogenes: a promising vector for tumor immunotherapy.
Ding YD, Shu LZ, He RS, Chen KY, Deng YJ, Zhou ZB, Xiong Y, Deng H. Ding YD, et al. Front Immunol. 2023 Oct 6;14:1278011. doi: 10.3389/fimmu.2023.1278011. eCollection 2023. Front Immunol. 2023. PMID: 37868979 Free PMC article. Review. - Mesothelin-targeted CAR-T therapy combined with irinotecan for the treatment of solid cancer.
Zhu Y, Zuo D, Wang K, Lan S, He H, Chen L, Chen X, Feng M. Zhu Y, et al. J Cancer Res Clin Oncol. 2023 Nov;149(16):15027-15038. doi: 10.1007/s00432-023-05279-9. Epub 2023 Aug 23. J Cancer Res Clin Oncol. 2023. PMID: 37612388 - A Prospective Clinical Trial to Evaluate Mesothelin as a Biomarker for the Clinical Management of Patients With Esophageal Adenocarcinoma.
Byun AJ, Grosser RA, Choe JK, Rizk NP, Tang LH, Molena D, Tan KS, Restle D, Cheema W, Zhu A, Gerdes H, Markowitz AJ, Bains MS, Rusch VW, Jones DR, Adusumilli PS. Byun AJ, et al. Ann Surg. 2023 Nov 1;278(5):e1003-e1010. doi: 10.1097/SLA.0000000000005885. Epub 2023 Apr 27. Ann Surg. 2023. PMID: 37185875
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical